Anavex Life Sciences (AVXL)
(Real Time Quote from BATS)
$6.38 USD
-0.20 (-3.04%)
Updated Aug 2, 2024 10:30 AM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
AVXL 6.38 -0.20(-3.04%)
Will AVXL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AVXL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AVXL
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails
AVXL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
Other News for AVXL
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
Buy Rating Affirmed for Anavex Life Sciences on Blarcamesine’s Promising Alzheimer’s Treatment Potential
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX?2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
Anavex announces preclinical results from study of ANAVEX2-73
Anavex: An Update To Their Phase 2b/3 Alzheimer's Trial Data